Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 7924153, 9 pages
https://doi.org/10.1155/2018/7924153
Research Article

Retrospective Analysis of Intravaginal Brachytherapy in Adjuvant Treatment of Early Endometrial Cancer

1Department of Oncology, Medical University of Lublin, Jaczewskiego 7, Lublin, Poland
2Department of Brachytherapy, St. John’s Oncology Center of Lublin, Jaczewskiego 7, Lublin, Poland
3Department of Gynecology, St. John’s Oncology Center of Lublin, Jaczewskiego 7, Lublin, Poland

Correspondence should be addressed to Paweł Cisek; ue.airetni@kesicp

Received 30 August 2017; Revised 20 December 2017; Accepted 28 December 2017; Published 21 February 2018

Academic Editor: John P. Geisler

Copyright © 2018 Paweł Cisek et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The aim of this study was to determine the role of adjuvant endovaginal brachytherapy HDR (High Dose Rate) or observation, as well as identification of risk factors of tumor recurrence. The study included 178 women after radical hysterectomy. All patients belonged to the group of low- and medium-risk stage I FIGO. Analysis consisted of 3-, 5-, and 10-year OS, DFS, and LRFS in both groups. Follow-up was more than 6.5 years. The 5-OS, 5-DFS, and 5-LRFS were 93%, 96%, and 98% in the treated group and 95%, 94%, and 96% in the observed group, respectively. These differences were not statistically significant. There was a statistically significant difference in 5-OS in the treated group, between low- and medium-risk subgroups (100% versus 87.55%, ). There was a better prognosis among the patients with FIGO IA compared to FIGO IB (5-DFS, 97 versus 86%, ). Among the risk factors, there were only statistically significant differences in the 5-OS, between the ages of ≤ 70 years and >70 years. Use of brachytherapy may affect the reduction in the number of local recurrences at the vaginal stump (6% versus 2%). This is particularly noticeable in the low-risk subgroup (9% versus 0%).